Oncology Business Management | Specialty

How to Properly Utilize MRD Testing

August 29th 2017

An Overview of Minimal Residual Disease Testing

August 29th 2017

Understanding MRD Testing in CLL

August 29th 2017

CLL: MRD Testing Platforms

August 29th 2017

MRD Timepoints in CLL

August 29th 2017

CLL: Value of MRD Testing

August 29th 2017

Goals of Therapy in CLL

August 29th 2017

Palliative Care Consultations Significantly Reduce Healthcare Utilization

August 29th 2017

End-of-life palliative care consultations can significantly reduce healthcare utilization, according to a broad-based population study published in the Journal of Oncology Practice.

Artificial Intelligence Is Still a Long Way From Understanding the Subtlety of a Texas Metaphor

August 27th 2017

It is not far-fetched to believe that, one day soon, automated systems will be able to obtain payer approval for therapies without any human involvement.

What If You Cannot Afford CAR T-Cells?

August 26th 2017

Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.

Cota-Watson Effort Aims at Optimal Cost Margins as Well as Improved Care

August 25th 2017

Investigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.

FDA Approves Inotuzumab Ozogamicin for ALL

August 17th 2017

The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16th 2017

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.

Precision Medicine Moves Forward, 1 Validated Biomarker at a Time

August 15th 2017

This commentary from Maurie Markman, MD, highlights a critical required component for the development of effective novel antineoplastic strategies through the process widely known as precision cancer medicine.

PROs Save Money, Lives, and Improve QoL

August 9th 2017

Despite improved outcomes with new treatment and targeted therapies, patients with cancer continue to be afflicted by distressing symptoms and serious toxicities, which affect daily functioning and quality of life.

Arizona Oncology Center Uses State of the Art Facility to Gain Market Share

August 8th 2017

Architects can tailor new buildings to oncology’s specific needs and Arizona Oncology built its newest facility from the ground up rather than renting generic offices.

Using Population Science to Fill in the Blanks

August 7th 2017

When it comes to treating older populations for cancer, it’s often the case that the only available data are based on trials of younger patients in far healthier condition.

MedPAC's Latest Part B Proposals Would Raise the Cost of Care

August 6th 2017

The Medicare Payment Advisory Commission (MedPAC) voted to approve several proposals aimed at decreasing Medicare spending for Part B physician-administered drugs.

Not All Care Pathways Lead to Optimal Outcomes and Cost

August 5th 2017

To optimize clinical outcomes and reduce the total cost of care, it is important to limit physicians’ choices of care.

FDA Grants Frontline Alectinib Priority Review for ALK-Positive NSCLC

August 3rd 2017

The FDA has granted a priority review to a supplemental new drug application for alectinib (Alecensa) for the frontline treatment of patients with ALK-positive locally advanced or metastatic non–small cell lung cancer.